About 75% of the weight lost on tirzepatide was fat and 25% was lean mass — the same ratio seen with placebo, just at a much larger scale.
75% fat / 25% leanThe ratio of fat-to-lean mass loss was consistent across tirzepatide and placebo groups and across all subgroups analyzed
What the researchers found
Tirzepatide produced a 21.3% reduction in total body weight at 72 weeks, composed of a 33.9% loss in fat mass and a 10.9% loss in lean mass. In the placebo group, these figures were 5.3%, 8.2%, and 2.6% respectively (p < 0.001 for all comparisons).
Critically, the composition of weight lost was approximately 75% fat mass and 25% lean mass in both the tirzepatide and placebo groups. This ratio remained consistent across subgroups defined by sex, age, baseline BMI, and baseline fat mass.
Why it matters
A major concern with GLP-1 and dual-agonist weight loss drugs is that people may lose too much muscle along with fat. This study provides reassurance that tirzepatide's weight loss follows the typical biological pattern — about three-quarters fat, one-quarter lean mass — rather than causing disproportionate muscle wasting. The consistency of this ratio across subgroups strengthens the finding.
How the study worked
This was a substudy of 160 participants from the larger SURMOUNT-1 randomized controlled trial (2,539 total). Participants had obesity or overweight and underwent dual-energy X-ray absorptiometry (DXA) body scans at baseline and at week 72. Results were pooled across tirzepatide doses (5, 10, and 15 mg) and compared with placebo. Post hoc subgroup analyses examined consistency across sex, age, BMI, and baseline fat mass categories.
What this study cannot tell us
The substudy included only 160 of the 2,539 SURMOUNT-1 participants, which may not be fully representative. Tirzepatide doses were pooled, so dose-specific effects on body composition could not be assessed. The study did not evaluate whether lean mass loss impacted physical function, strength, or metabolic rate. DXA measures total lean mass, which includes water and organs — not just skeletal muscle.
How to read the evidence
This is a substudy from a Phase 3 randomized, double-blind, placebo-controlled trial (SURMOUNT-1) using objective DXA body scans, giving it strong methodological rigor, though the substudy sample was relatively small.
When this study was published
Published in 2025, this is current and highly relevant as tirzepatide use continues to expand for obesity treatment.
The bigger picture
As tirzepatide and similar drugs become widely used for obesity, understanding what type of tissue is being lost is essential. This body composition data from SURMOUNT-1 helps answer one of the most frequently asked questions about these medications and informs clinical guidance around exercise and protein intake during treatment.
Questions still open
- Does the lean mass lost on tirzepatide include clinically meaningful muscle loss, or is much of it water and organ mass?
- Would resistance training during tirzepatide treatment shift the ratio to preserve more lean mass?
- Do body composition outcomes differ at the individual tirzepatide dose levels (5 mg vs. 10 mg vs. 15 mg)?
Common questions
Does tirzepatide cause you to lose more muscle than fat?
Was the body composition effect different for men versus women?
Read the original research
Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.
Diabetes, obesity & metabolism, 27(5), 2720-2729
Citation
Look, Michelle; Dunn, Julia P; Kushner, Robert F; Cao, Dachuang; Harris, Charles; Gibble, Theresa Hunter; Stefanski, Adam; Griffin, Ryan. (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.. Diabetes, obesity & metabolism, 27(5), 2720-2729. https://doi.org/10.1111/dom.16275